Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

The drug reduced weight by 16 pounds, on average, at the highest dose The pill could make treatment easier for people who don ...

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

Eli Lilly's new pill shows impressive results, matching Ozempic in lowering weight and blood sugar levels for diabetes ...

Stock futures are little changed Wednesday night after a steep sell-off in the prior session. Futures tied to the Dow Jones ...

The positive data gives Eli Lilly the green light to file the drug with the FDA by the end of the year for a weight loss ...

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest ...

The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...